Natera reports preliminary Q2 revenue ~$138-141M (+60% YoY); Women's Health cash flow breakeven

Natera, Inc.

2022-Q2 EPS reported -$2.06 revenue$294,342,000

Total revenue expected $138-141M vs $86.5M in Q2 2020, a record ~60% YoY growth.
Product revenue $135-137M, up ~70% YoY from $80.4M; processed ~370,000 tests (+58%).
Women's Health business achieved cash flow breakeven for the first time in Q2 2021.
Loss from operations widened to $113-117M from $51.7M due to higher R&D and SG&A costs.
On May 11, 2021 entered a development/option deal: paid $10M; option to buy assets for $290M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.